|
Drug Treatment for Lysosomal Storage Disorders (All Ages), Commissioning Policy (CP55), October 2024 (PDF, 696Kb)
|
|
Sapropterin for treating hyperphenylalaninaemia (HPA) in phenylketonuria (PKU) and tetrahydrobiopterin (BH4) disorders, Policy Position (PP223), January 2023 (PDF, 464Kb)
|
|
Volanesorsen for treating familial chylomicronaemia syndrome, Policy Position Statement, (PP217). October 2021 (PDF, 285Kb)
|